Across TCGA pan-cancer cohorts, CHSY3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CHSY3 data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CHSY3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHSY3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, UCEC, and LUAD are the cancer types where CHSY3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.123	0.805	<.001	42	view →
UCEC	DFS	Median	II,III,IV	0.928	0.435	.019	16	view →
LUAD	OS	Median	II,III,IV	0.171	0.750	.002	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CHSY3 tumor-vs-normal RNA expression · all CHSY3 data types